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Abstract 
Background: An infection‑immune association of periodontal disease with rheumatoid arthritis has been suggested. 
This study aimed to investigate the effect of pre‑existing periodontitis on the development and the immune/inflam‑
matory response of pristane‑induced arthritis.
Methods: We investigated the effect of periodontitis induced by ligature placement and Porphyromonas gingivalis (P. 
gingivalis) infection, in combination with Fusobacterium nucleatum to promote its colonization, on the development 
of pristane‑induced arthritis (PIA) in rats (Dark Agouti). Disease progression and severity of periodontitis and arthritis 
was monitored using clinical assessment, micro‑computed tomography (micro‑CT)/intraoral radiographs, antibody 
response, the inflammatory markers such as α‑1‑acid glycoprotein (α‑1‑AGP) and c‑reactive protein (CRP) as well as 
cytokine multiplex profiling at different time intervals after induction.
Results: Experimentally induced periodontitis manifested clinically (P < 0.05) prior to pristane injection and pro‑
gressed steadily until the end of experiments (15 weeks), as compared to the non‑ligated arthritis group. Injection 
of pristane 8 weeks after periodontitis‑induction led to severe arthritis in all rats demonstrating that the severity of 
arthritis was not affected by the pre‑existence of periodontitis. Endpoint analysis showed that 89% of the periodon‑
titis‑affected animals were positive for antibodies against arginine gingipain B and furthermore, the plasma antibody 
levels to a citrullinated P. gingivalis peptidylarginine deiminase (PPAD) peptide (denoted CPP3) were significantly 
(P < 0.05) higher in periodontitis rats with PIA. Additionally, there was a trend towards increased pro‑inflammatory and 
anti‑inflammatory cytokine levels, and increased α‑1‑AGP levels in plasma from periodontitis‑challenged PIA rats.
Conclusions: Pre‑existence of periodontitis induced antibodies against citrullinated peptide derived from PPAD in 
rats with PIA. However, there were no differences in the development or severity of PIA between periodontitis chal‑
lenged and periodontitis free rats.
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Background
Periodontitis is one of the most common infectious 
inflammatory diseases of mankind, affecting up to 30% of 
the world population [1, 2]. Epidemiological and clinical 
studies have linked this highly prevalent disease to other 
systemic inflammatory diseases such as cardiovascular 
diseases, chronic obstructive pulmonary disease, dia-
betes, obesity and rheumatoid arthritis (RA) [3–7]. In 
periodontitis, P. gingivalis has been demonstrated to 
be a key pathogen in the shift in composition of tooth-
surface microbiota, from commensal to pathogenic [8]. 
In humans, infection with P. gingivalis and other impor-
tant periodontal pathogens of the “red complex” [9, 
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that promote their colonization such as Fusobacterium 
nucleatum (F. nucleatum) [11], initiates an inflammatory 
response in the periodontium, which may become chronic 
and lead to destruction of tooth-supporting structures. 
The signs of an on-going inflammation are visible not 
only locally in the periodontal pockets but also systemi-
cally [12] as elevated levels of inflammatory mediators are 
present in the blood of patients with periodontitis [13]. 
This may have a direct bearing on the development of 
atherosclerotic plaque and aggravation of other chronic 
inflammatory diseases [14], including RA, reported to be 
increased in population affected by periodontitis [15, 16].
A potential relationship between RA and periodonti-
tis has been proposed since these two diseases, although 
different in terms of their etiological background, dem-
onstrate several similarities including shared risk fac-
tors such as smoking and pathophysiological features 
including a similar set of effector inflammatory cells, pro-
inflammatory cytokines, and other mediators that drive 
bone destruction [8, 17–21]. Up to 1% of the population 
worldwide suffers from RA, a painful chronic inflam-
matory autoimmune condition, where synovial joint 
inflammation destroys cartilage and bone causing irre-
versible joint damage [22]. The etiology of RA is not yet 
fully understood, however a complex interplay of genetic, 
environmental, hormonal and infectious risk factors are 
involved [22]. Moreover, antibodies to citrullinated pro-
tein antigens (ACPAs) have a high disease specificity and 
are associated with more aggressive disease course and 
joint destruction in RA [23]. Therefore, the processes 
linked to the generation of ACPAs are an area of inter-
est in studies investigating the pathogenesis of this dis-
ease. Intriguingly, P. gingivalis secretes a unique bacterial 
enzyme, peptidylarginine deiminase (PAD), able to cit-
rullinate proteins [17]. Citrullinated fibrin in synovium 
of RA patients is a major target for RA-specific ACPAs, 
making P. gingivalis PAD (denoted PPAD) a potential 
contributor to the arthritis-related immune response 
[17, 24, 25]. PPAD acts together with another major vir-
ulence factor, known as arginine gingipain B (RgpB), an 
arginine-specific extracellular protease expressed on the 
surface of the bacterial outer membrane [25]. RgpB has 
been shown to be essential for the ability of P. gingivalis 
to citrullinate peptides since the citrullination by PPAD, 
i.e. conversion of peptidylarginine into peptidylcitrul-
line, occurs after degradation by RgpB [25]. Moreover, 
antibody levels to RgpB are elevated in patients with RA 
compared to controls without RA [26]. According to an 
etiological hypothesis, actions of PPAD lead to a chronic 
exposure of citrullinated proteins in the inflamed peri-
odontium, which triggers loss of immune tolerance and 
ACPA production [17]. Therefore P. gingivalis could rep-
resent a link between periodontitis and RA. In support 
of this hypothesis, it has been shown that citrullinated 
proteins are present in the inflamed periodontium and 
ACPAs have been detected in sera from patient with 
periodontitis [27, 28]. Moreover, it has been shown that 
ACPAs targeting human citrullinated α-enolase cross-
react with P. gingivalis enolase, creating the basis of a 
molecular mimicry hypothesis between periodontitis 
and RA [18]. Also, antibodies against P. gingivalis, as 
well as P. gingivalis DNA, has been found in serum and 
synovial fluid in patients with RA [29, 30]. In 2010, Bar-
told et  al. showed that induction of chronic inflamma-
tion by implanting polyurethane sponges impregnated 
with P. gingivalis resulted in rapid development of severe 
arthritis in Dark Agouti (DA) rats [31]. Additionally, 
rats with mycobacteria-induced adjuvant arthritis have 
demonstrated periodontal bone loss and elevated levels 
of matrix metalloproteinases (MMPs), tumor necrosis 
factor-α (TNF-α) and interleukin-1β (IL-1β) in gingival 
tissue [32]. Although several studies indicate that there 
is a relationship between periodontitis and RA, recent 
reviews conclude that a direct role of P. gingivalis in this 
temporal relationship still remains elusive [33]. The aim 
of this study was therefore to explore the effect of pre-
existing experimental periodontitis, induced by ligatures 
and periodontal pathogens P. gingivalis in combina-
tion with F. nucleatum on the development of arthritis, 




Twenty-six inbred adult male Dark Agouti (DA) rats 
(165–220  g) were included in this study, to investigate 
the effect of pre-existing periodontitis, induced by liga-
ture and P. gingivalis infection in combination with F. 
nucleatum on the development of arthritis. The animals 
were bred and kept at the environmentally standard-
ized animal facility, at Medical Inflammation Research, 
under specific pathogen free conditions, as previously 
described [35]. The rats were housed in individually ven-
tilated cages (IVC rack), and received water and stand-
ard pellets ad libitum. Before starting the study, approval 
was obtained from the ethical committee (the Stock-
holm North Animal Ethics Committee, approval num-
ber Dnr N67/10 and N143/10). The rats were randomly 
divided into groups: PA—the experimental periodontitis 
group with induced arthritis (n = 10) and A—the arthri-
tis induced group without periodontitis (non-ligated) 
(n  =  12). Additionally, a group of healthy control rats 
without arthritis or periodontitis (non-ligated and non 
PIA-induced) (n = 4) was included. One rat from the PA 
group was excluded in the beginning of the experiment 
due to gender mix up (female). In the PA group induction 
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of experimental periodontitis was performed for 8 weeks 
prior to pristane injection, using a ligature model in 
combination with recurring swabs with P. gingivalis and 
F. nucleatum (known to promote colonization of P. gin-
givalis adjacent to the affected teeth) [11] in order to 
facilitate a more generalized form of oral infection. After 
8 weeks of experimental periodontitis, PIA was induced 
in both PA and A group and the development of arthritis 
was monitored for an additional 7 weeks. After 15 weeks, 
evaluated as experimental endpoint, all animals were 
euthanized using CO2.
Experimental periodontitis
For induction of experimental periodontitis (PA group), 
the rats were anesthetized using isoflurane, and 4-0 silk 
ligatures (Johnson & Johnson International New Brun-
swick, NJ, USA) were placed around the cervical part 
of the second upper molars on both sides and knotted 
mesio-palatally [36]. Every 10  days, a dental examina-
tion was performed where the ligatures were controlled 
and tooth mobility was assessed by a trained dentist, and 
by two dentists at endpoint, to supervise the course of 
the experimental periodontitis. In case of partially loos-
ened or missing ligatures, new ligatures were placed. To 
facilitate the development and progression of periodon-
titis, each dental examination was followed by swabs 
containing P. gingivalis CCUG 14449 in combination 
with F. nucleatum ATCC 10953 (known to promote the 
colonization of P. gingivalis) [11] reconstituted in 4% 
Gantrez copolymer medium (International Specialty 
Products, Köln, Germany) to promote bacterial adhesion 
and retention in the oral cavity. Additional swabs were 
administered once more in-between the times for dental 
examination. Rats in the arthritis non-ligated group (A) 
and the healthy control group received swabs with 4% 
Gantrez medium only.
The severity of experimentally induced periodonti-
tis was monitored using a clinical manifestation grad-
ing scale of tooth mobility (modified from Lindhe and 
Nyman 1975) [37], as well as by assessment of radiologi-
cal alveolar bone levels at endpoint (week 15) [36]. At 
all consecutive time points the tooth mobility, of the left 
and right second maxillary molars, was assessed in all 
animals. Tooth mobility grading (with a maximum score 
of 6 points/rat) represented 1, 2 or 3 points correspond-
ing to mobility grade 1 = slight mobility in buccolingual 
direction, 2 =  mobility in buccolingual and mesiodistal 
directions or 3 =  vertical mobility [38]. Zero (0) points 
indicated no clinical manifestation of periodontitis. The 
total mean score (±SE) for each group was calculated for 
each time point. For assessment of radiological alveolar 
bone levels, the upper jaws of the experimental animals 
were separated at the intermaxillary suture, X-rayed 
using a standard intraoral X-ray unit (Planmeca, Hel-
sinki, Finland) and analyzed using the Planmeca Romexis 
software, as previously described [36]. The separated jaws 
were placed on a Planmeca ProSensor and exposed for 
0.16 s to 60 kV and 8 mA. The alveolar bone levels were 
measured from a straight line marking of the occlusal 
surface of the upper second molars, to the marginal 
bone at the mesial and distal interproximal sites [36]. 
The measurements were performed blindly and inde-
pendently by two calibrated dentists. For further illustra-
tion of the alveolar bone loss and corresponding arthritic 
changes in limbs, the intact sculls of representative ani-
mals were scanned together with front and hind paws 
using micro-computed tomography (micro-CT).
Experimental arthritis
To induce PIA, we gave a single intradermal injec-
tion at the dorsal side of tail with 100  µl of pristane 
(2,6,10,14-tetramethylpentadecane, 95% Arcos Organics, 
Morris Plains, NJ, USA) 8 weeks after experiment start 
in both the PA group and non-ligated A group. Assess-
ment of arthritic changes in limbs was performed in the 
regions of interest to monitor the destruction of articular 
cartilage and ankylosis of the joints, as well as inflamma-
tory response of the synovium. A visual scoring system 
of 1–60 points per rat was used as described previously 
[39]. In brief, 1 point was given for each knuckle or toe 
with inflammation and up to 5 points for an affected 
ankle or wrist, in total 15 points per paw. All scoring was 
performed blindly and independently by two examiners. 
Weight changes of each rat were monitored during the 
course of the experiment as an objective measure of dis-
ease severity [35].
Micro‑computed tomography
Fixed crania, front and hind paws were scanned using 
nanoScan PET/CT (Mediso Ltd, Budapest, Hungary) 
to illustrate the alveolar bone loss and arthritic changes 
in limbs. The three-dimensional images of the limbs 
and maxilla were reconstructed and calibrated to the 
Hounsfield scale with an effective isotropic voxel size 
of 0.02 mm. Imaging of paws was conducted with Able-
Software 3D-Doctor.
Bacterial culture and preparation
Porphyromonas gingivalis (CCUG 14449) and F. nuclea-
tum (ATCC 10953) obtained from Culture Collection, 
University of Gothenburg, Sweden and American Type 
Culture Collection, Germany, respectively, were cultured 
at 37 °C, on anaerobic blood agar plates (Brucella/Brucella 
supplemented with heme and vitamin K). Bacterial swab 
mixtures of P. gingivalis and F. nucleatum were prepared 
at the density of 2 ×  108 and 1 ×  108 cells/ml (counted 
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using Bürker counting chamber), respectively. The bac-
terial mixtures (transported to the animal facility in an 
anaerobic cultivation system) were vortexed prior appli-
cation to achieve homogenous distribution and applied 
around the second upper molar, 50 µl bacterial mixture on 
each side (100 µl/rat). In parallel, additional bacterial mix-
tures were also prepared and transported in an anaerobic 
cultivation system to detect the survival of P. gingivalis/F. 
nucleatum. For the detection of bacteria at endpoint, liga-
ture and mucosal samples were cultured. Mucosal swabs 
were plated on Brucella agar for P. gingivalis culture, and 
on Brucella agar supplemented with heme and vitamin 
K for F. nucleatum. Ligature samples transported in 1 ml 
FAB were resuspended in PBS (dilution 1:100), and 100 µl 
of each sample was then plated for P. gingivalis/F. nuclea-
tum on corresponding agar plates. Each ligature sample 
was also cultured undiluted. Cultures were incubated 
at 37  °C in anaerobic conditions for 5–7  days. Colonies 
of potential P. gingivalis/F. nucleatum were regrown on 
new agar plates, for purification and identification. Gram 
staining was used to confirm identification. Brucella agar 
(MIK1533) and Brucella agar supplemented with heme 
and vitamin K (MIK3657) were purchased from Substrate 
unit, Karolinska University Hospital (Huddinge, Sweden).
Sampling and processing
Blood samples (0.2  ml) were collected from the tail of 
all the rats at the start and during consecutive controls 
(every 10 days) of the experimental period of 15 weeks. In 
addition, blood from the heart was collected by cardiac 
puncture (10 ml) at the end of the experimental period. 
Ligatures, both loosened during the course of experi-
ment and those collected at the end of experiment were 
transferred either into fastidious anaerobe broth (FAB) 
and transported to the laboratory on ice (right side) or 
snap frozen in liquid nitrogen and transferred to −80 °C 
for subsequent analysis (left side). At the end of experi-
ment, week 15, mucosal surfaces (buccal and dorsum of 
the tongue) were swabbed for bacteria using a sterile cot-
ton swab. Swabs were placed into FAB, transported on 
ice and stored at 4  °C until analysis (within 24  h). Both 
hind paws, right front paw and heads following decapita-
tion and skin removal, were all collected in 4% phosphate 
buffered formaldehyde and stored at 4 °C until micro-CT. 
Left front paw was snap frozen in liquid nitrogen and 
transferred to −80 °C for real-time qPCR analysis.
Extraction of DNA from joints and dental ligatures
Genomic DNA (gDNA) was isolated and purified from 
the silk ligatures or tissues using QIAamp DNA Mini Kit 
(Qiagen, USA) [40]. Briefly, ligatures and bacterial cells 
were pelleted by centrifugation, resuspended in tissue lysis 
buffer (ATL) followed by overnight lysis with proteinase 
K (Qiagen) at 56 °C and purified using ethanol-containing 
buffers according to manufacturer’s instructions. gDNA 
was eluted in nuclease-free water, followed by spectropho-
tometric quantification and quality assessment (A260) with 
NanoVue spectrophotometer (GE Healthcare Bio-Science, 
Uppsala, Sweden) and stored at −20  °C until amplifica-
tion by real-time qPCR. For gDNA isolation from inflam-
matory infiltrates, metacarpophalangeal joints including 
connective tissue of the joint capsule were dissected and 
homogenized by gently crushing after submerging in liq-
uid nitrogen followed by proteinase K treatment as above. 
Purified diluted gDNA from the P. gingivalis strain used in 
this animal study, CCUG 14449, as well as strains 33277 
and W83 were used as positive controls.
Detection of P. gingivalis with real‑time qPCR analysis
PCR reactions were performed on DNA samples from 
ligatures and tissues using the universal primer 16S to 
detect the presence of non-specific bacterial DNA species 
and with P. gingivalis-specific primer to detect the pres-
ence of P. gingivalis [41]. The assays were carried out using 
7500 Fast Real-Time qPCR System (Applied Biosystems, 
Foster City, CA USA). Triplicate samples were assayed 
in a total volume of 20  μl, containing 40  ng of template 
gDNA solution, TaqMan Universal PCR Master Mix (2x) 
(Applied Biosystems, Foster City, CA, USA), and the spe-
cific set of primers (final concentration 18 μM) and probe 
(final concentration 5  μM) (Cybergene AB, Solna, Swe-
den), corresponding to 900  nM of forward and reverse 
primer and 250 nM of the probe at the final 1x concentra-
tion. After an initial incubation step of 2 min at 50 °C and 
denaturation for 10 min at 95 °C, 40 PCR cycles (95 °C for 
15  s, 60  °C for 1  min) were performed. Three biological 
replicates were used for calculating the means and stand-
ard deviations for each ligature/animal (total n = 9). The 
experiment was repeated on two different occasions, on 
loosened ligatures and those collected at the end of exper-
imental protocol. The primers and probes used for the 
analysis were: P. gingivalis forward primer 5′-GCG CTC 
AAC GTT CAG CC-3′, reverse primer 5′-CAC GAA 
TTC CGC CTG C-3′, probe 5′-6FAM-CAC TGA ACT 
CAA GCC CGG CAG TTT CAA-TAMRA-3′; 16S DNA 
universal forward primer 5′-TGG AGC ATG TGG TTT 
AAT TCG A-3′, reverse primer 5′-TGC GGG ACT TAA 
CCC AAC A-3′, probe 5′-6FAM-CAC GAG CTG ACG 
ACA RCC ATG CA-TAMRA-3′.
Measurements of α‑1‑acid glycoprotein (α‑1‑AGP), 
C‑reactive protein (CRP), arginine gingipain B (RgpB), 
α‑enolase (CEP‑1) and citrullinated PPAD peptide (CPP3) 
levels
Plasma levels of α-1-AGP and CRP were assessed using 
ELISA kits according to the manufacturer protocols (Life 
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Diagnostics Inc. West Chester, PA, USA and Sigma-
Aldrich, St.Louis, MO, USA, respectively). Briefly, plasma 
rat samples were diluted 1:40,000 and incubated in 
microtiter wells with solid phase affinity purified anti-rat 
α-1-AGP antibodies for 45  min or biotinylated rat CRP 
antibodies for 1 h, followed by incubation with horserad-
ish peroxidase conjugate and subsequent detection with 
tetramethylbenzidine (TMB) reagent. The optical densi-
ties of α-1-AGP and CRP were measured spectrophoto-
metrically and plasma levels were calculated using mean 
absorbance from standard curve and reference standards 
at 450 nm. The concentrations of α-1-AGP and CRP were 
expressed as mean (μg/ml ± SE).
Citrullinated and uncitrullinated arginine peptides 
(synthetic) from α-enolase (CEP-1/REP-1) and PPAD 
(CPP3/RPP3), as well as antibodies against RgpB pro-
tein were analyzed using an in-house peptide ELISA [42]. 
Briefly, plasma samples were diluted 1:2 for CPP3/RPP3, 
1:20 for CEP-1/REP-1 and 1:50 for RgpB in buffer (1% 
BSA, 350 mM NaCl, 10 mM Tris–HCl, 1% Triton X-100, 
0.1% SDS) and incubated overnight in high-binding 
plates (MaxiSorp, Nunc) coated with CPP3/RPP3 (10 μg/
ml), CEP-1/REP-1 (2.5  μg/ml) or RgpB protein (3.4  μg/
ml). Plates were washed in PBS-Tween (0.05%) and incu-
bated with HRP-conjugated goat anti-rat IgG (Jackson 
Immuno Research Inc, West Grove, PA, USA) at room 
temperature for 1  h. Antibodies, measured in arbitrary 
units (expressed as mean AU/ml ±  SE), were detected 
using TMB reagent (Sigma-Aldrich, St. Louis, MO, USA) 
and calculated based on a standard curve from a seri-
ally diluted highly positive serum pool. Absorbance was 
measured at 450 nm.
Cytokine profiling
The endpoint plasma concentrations of the cytokines 
[sensitivities in square brackets] tumor necrosis factor-α 
(TNF-α) [3  pg/ml], interleukin(IL)-1α [1  pg/ml], IL-1β 
[2 pg/ml], IL-2 [3 pg/ml], IL-4 [1 pg/ml], IL-5 [6 pg/ml], 
IL-7 [0.4  pg/ml], IL-10 [5  pg/ml], IL-12p70 [0.7  pg/ml], 
IL-13 [0.9  pg/ml], IL-17A [0.1  pg/ml], IL-18 [4  pg/ml], 
macrophage colony-stimulating factor (M-CSF) [0.4  pg/
ml], monocyte chemotactic protein 1 (MCP-1) [4  pg/
ml], macrophage inflammatory protein (MIP)-3α [0.7 pg/
ml], regulated on activation normal T cell expressed and 
secreted (RANTES) [3  pg/ml], erythropoietin (EPO) 
[8  pg/ml], granulocyte–macrophage colony-stimulating 
factor (GM-CSF) [0.6  pg/ml], growth-related oncogene/
keratinocyte-derived chemokine (GRO/KC) [0.6  pg/ml] 
and vascular endothelial growth factor (VEGF) [0.3  pg/
ml] were analyzed using multiplex Bio-Plex Pro™ Rat 
Cytokine 24-plex Assay and Bio-Plex 200 system (Bio-
Rad, Sweden). The concentrations of the cytokines were 
expressed as mean (range) pg/ml.
Statistical analysis
The statistical analyses were performed by using the sta-
tistical package IBM SPSS Statistics 21.0. For the alveo-
lar bone measurements, the results are expressed as 
mean  ±  SE and values calculated using the results of 
measurements from two calibrated dentists. Student’s t 
test (two-tailed) was used to analyze differences in alveo-
lar bone level between the groups. Comparisons between 
treatment groups according to separate cytokine levels, 
α-1-AGP and CRP levels in blood plasma and differ-
ences for citrullinated/uncitrullinated peptide levels in 
plasma were performed by using Wilcoxon rank sum test. 
P < 0.05 was considered statistically significant.
Results
Ligature and periodontal pathogen‑induced periodontitis
The intraoral and radiograph dental images of DA rats 
with PIA and experimental periodontitis (PA group), 
and PIA without periodontitis (A group) are illustrated 
in Fig.  1a–i. The evaluation of ligature and periodon-
tal pathogen-induced periodontitis, showed significant 
tooth mobility and alveolar bone loss after 15  weeks of 
experimental period, endpoint (Fig.  1b–e, j, k). Severe 
localized periodontitis, as assessed by tooth mobility 
score, manifested in all periodontitis-induced animals 
by week 6, prior to injection of pristane, and progressed 
further reaching plateau at week 9 (Fig.  1j). In contrast, 
neither the arthritis group without induced periodontitis 
(non-ligated) (A) nor the healthy controls rats (no perio-
dontitis and no arthritis) showed any clinical signs of per-
iodontitis, in terms of tooth mobility, during the course of 
the experiment (Fig. 1j and data not shown, respectively). 
Micro-CT scanning and assessment of alveolar bone level 
in intraoral radiographs showed significant (P  <  0.05) 
loss of alveolar bone at the end of experiment for the PA 
group (mean alveolar bone level 1.8 ± 0.02 mm), as com-
pared to the non-ligated arthritis group (mean alveolar 
bone level 1.4 ± 0.02 mm) (Fig. 1b–e, g–i, k). The alveolar 
bone level of the healthy control group (no periodontitis 
and no arthritis) was 1.5 ±  0.03  mm demonstrating no 
significant differences between the arthritis and healthy 
control group at the end of experiment.
To confirm presence of P. gingivalis and F. nucleatum 
in the site of inflammation, oral swabs and ligatures were 
collected at the end of the experiment (week 15) and cul-
tured on respective plates in anaerobic conditions. Mixed 
bacterial flora was present in all of the samples, generat-
ing around 5 × 102 CFU per sample (data not shown). F. 
nucleatum was identified in 6 out of 9 challenged animals 
(2 in oral swabs, 4 in ligature cultures). No viable P. gin-
givalis were detected in the cultures at endpoint although 
at the time of application of the bacterial swabs live P. gin-
givalis were detected using cultivation method (data not 
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shown). DNA samples isolated from ligatures at endpoint 
were tested using P. gingivalis-specific real-time qPCR 
primers. Using that technique, we were able to confirm 
the presence of P. gingivalis DNA in ligatures from all 
9 challenged animals (Additional file  1: Figure  S1a, b). 























































Fig. 1 Clinical manifestation of periodontitis and radiographic assessment of bone loss. a Intraoral photograph of the ligated second upper molar 
in a rat with arthritis and experimental periodontitis. b Radiograph image of bone volume around a second upper molar, c micro‑CT data (horizon‑
tal section) indicating bone loss around the upper molars and d, e 3D rendering of micro‑CT data of bone volume around maxillary molars in an 
arthritis rat with experimental periodontitis. f Intraoral photograph of the non‑ligated second upper molar of an arthritis rat without induced peri‑
odontitis. g Radiograph image of bone volume around the second upper molar, h micro‑CT data (horizontal section) indicating bone loss around 
the upper molars and i 3D rendering of micro‑CT data of bone volume around maxillary molars in a rat without induced periodontitis. j Mean tooth 
mobility score (±SE) in arthritis rats with periodontitis (n = 9) and without periodontitis (n = 12) throughout the experimental period of 15 weeks. 
k Distribution of mean alveolar bone level at endpoint in arthritis rats with periodontitis (n = 8) and without periodontitis (n = 10). *P < 0.05 was 
considered statistically significant. Circle indicates outliers. Gray line indicates time point of pristane injection. PIA pristane‑induced arthritis, PA rats 
with experimental periodontitis and PIA, A rats with PIA without periodontitis
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in synovial tissue of patients with active periodontitis 
have previously been reported [43], we also tested DNA 
isolated from metacarpophalangeal joint tissue of chal-
lenged animals. However, we were not able to detect any 
traces of P. gingivalis in these samples (data not shown).
Effect of pre‑existing periodontitis on the development 
of pristane‑induced arthritis
To explore the impact of pre-existing periodontitis on 
the initiation, rate of progression, and severity of arthri-
tis, the PIA model was adopted to quantify the contri-
bution of periodontal infection in the disease process. 
Prior to immunization with pristane, animals with liga-
tures showed no signs of systemic illness and gained 
weight at the same rate as animals without experimental 
periodontitis (non-ligated) (Fig.  2a). All animals in the 
periodontitis group showed clinical signs of periodon-
tal disease prior to injection of pristane (Fig.  1j). Mean 
arthritis score, based on evaluation of macroscopic 
inflammation (swelling and redness) in limbs, appeared 
around 2  weeks post pristane injection with a subse-
quently more severely developed arthritis leading at the 
end to a chronic relapsing disease course, as previously 
described [44]. The arthritis developed irrespectively of 
absence or presence of periodontitis, reaching maximum 
at 3–4  weeks post injection (Fig.  2b). For animals with 
periodontitis and arthritis (PA), the mean arthritis score 
(±SE) during experimental weeks 9–15 varied between 
0.1 ±  0.1 and 23 ±  2.9, as compared to 0.1 ±  0.08 and 
26  ±  1.9 for animals with arthritis only (A) (Fig.  2b). 
Micro-CT analysis of front and hind paws at the end of 
experiment confirmed our clinical findings showing that 
the pre-existence of periodontitis did not affect the sever-
ity of arthritis. Both PA and A groups showed markedly 
bone and cartilage changes compared to corresponding 
healthy animals as illustrated by micro-CT images in 
Fig. 3. Furthermore, the presence of periodontitis had no 
impact on mean weight change of pristane injected rats 
(Fig.  2a). Mean weight ±  SE varied between 212 ±  9.7 
and 251 ± 8.3 g in the PA group post pristane injection, 
as compared to 213 ± 6.2 and 257 ± 4.8 g in the A group. 
After 4  weeks post pristane injection (experiment week 
12), the mean arthritis scores decreased (Fig. 2b) indicat-
ing a period of remission, at this period the animals also 
started to gain weight (Fig. 2a).
Effect of pre‑existing periodontitis on α‑1‑AGP, 
CRP and cytokine/chemokine response 
during pristane‑induced arthritis
α-1-AGP is an acute phase protein that is effected by 







































































Fig. 2 Effect of pre‑existing periodontitis on weight changes, arthritis 
disease severity and α‑1‑AGP levels. a Mean changes in weight 
(grams ± SE) in arthritis rats with and without periodontitis through‑
out the experimental period of 15 weeks. b Mean arthritis disease 
severity score (±SE) of front and hind paws in arthritis rats with and 
without periodontitis, up to 7 weeks after pristane injection. c Mean 
plasma concentrations (μg/ml ± SE) of α‑1‑AGP in arthritis rats with 
and without periodontitis throughout the experimental period of 
15 weeks. The results are presented as mean values (±SE) for the 
groups PA (n = 9) and A (n = 12) at different time‑points throughout 
the experiment. Gray line indicates time point of pristane injection. 
PIA pristane‑induced arthritis, PA rats with experimental periodontitis 
and PIA, A rats with PIA without periodontitis
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mean plasma levels of α-1-AGP were comparable for 
animals affected with periodontitis (varying between a 
mean of 186 ± 43 and 334 ± 47 μg/ml) and periodontally 
healthy rats from the non-ligated arthritis group (varying 
between 214 ± 25 and 313 ± 28 μg/ml) (Fig. 2c). Levels 
of α-1-AGP increased rapidly in both groups after immu-
nization and peaked at around 3 weeks after immuniza-
tion, although no significant differences between groups 
were observed. However, a tendency (P = 0.07) towards 
higher plasma α-1-AGP levels in periodontitis-affected 
rats was seen at endpoint following pristane injection 
(mean: rats with periodontitis and induced arthritis, PA, 
422 ± 65 to 1386 ± 250 μg/ml; rats with arthritis only, A, 
358 ± 49 to 1010 ± 156 μg/ml) (Fig. 2c). Similar results 
were obtained when analyzing CRP levels showing 
increased CRP after the induction of PIA for both the PA 
(mean concentration 748 ±  45  μg/ml) and the A group 
(mean concentration 813 ± 72 μg/ml), with no significant 
differences between the groups. Moreover, no differences 
were observed between the PA and A group neither at 
baseline (510 ±  53 and 469 ±  110  μg/ml, respectively), 
nor at endpoint (525 ± 86 and 598 ± 53 μg/ml, respec-
tively) (Fig. not shown).
Considering the importance of cytokine/chemokine 
interplay on development and progression of arthritis, we 
analyzed the levels of multiple cytokines in plasma. No 
significant difference in levels of: TNF-α, IL-1α, IL-1β, 
IL-2, IL-4, IL-5, IL-7, IL-10, IL-12, IL-13, IL-17, IL-18, 
EPO, GM-CSF, M-CSF, GRO/KC, MIP-3α, RANTES, 
VEGF and MCP-1 were observed (Table 1). Although the 
differences were not statistically significant, we observed 
that the mean levels of pro-inflammatory cytokines were 
consistently higher in the case of arthritic animals with 
accompanying periodontal disease (Table 1).
Fig. 3 Micro‑CT images and visual appearance of front and hind paws for assessment of arthritic changes. Micro‑CT images of bone and tissue 
changes in front and hind paws of animals affected with experimental periodontitis and induced arthritis (PA), arthritis without periodontitis (A) and 
corresponding images of DA rats without induced arthritis or periodontitis (Healthy) at the time‑point of 15 weeks; and visual appearance of front 
and hind paws at endpoint
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Effect of pre‑existing periodontitis on the antibody 
response to RgpB and PPAD
To confirm that challenging animals with P. gingivalis 
successfully elicited an immune response, we screened 
all plasma samples for the presence of antibodies 
against RgpB. Not surprisingly, considering our clini-
cal findings, the majority (8 of 9) of the animals in the 
periodontitis and arthritis group (PA) were positive for 
antibodies against RgpB, whereas no anti-RgpB antibod-
ies were detected in the arthritis group without peri-
odontitis (A) or in the healthy control group (Fig. 4a).
In order to investigate the capacity of P. gingivalis to 
generate antibodies against citrullinated α-enolase and 
PPAD in the periodontitis ligature model, an ELISA-
based approach was used. Antigens included a syn-
thetic citrullinated peptide derived from the C-terminal 
region of PPAD (CPP3) [46, 47] and the immunodomi-
nant CEP-1 peptide derived from citrullinated human 
α-enolase [48]. Animals in the PA group had signifi-
cantly (P  <  0.05) higher levels of antibodies to CPP3 as 
compared to the arthritis group, while there were no dif-
ferences in antibody response to the corresponding argi-
nine-containing (i.e. non-citrullinated) control peptide 
RPP3 between these groups (Fig. 4b). Moreover, the lev-
els of CPP3 and RPP3 did not significantly differ between 
the arthritis-only animals (A) and the healthy control rats 
(Fig.  4a, b). None of the animals were positive for anti-
bodies to CEP-1 or the non-citrullinated control REP-1 
peptide (data not shown).
Discussion
There is growing evidence of a link between RA and peri-
odontitis reflected in shared chronic nature of the inflam-
matory responses, as well as a number of environmental 
factors, including smoking and the periodontal pathogen 
P. gingivalis [49]. In this study we demonstrate, for the 
first time, the presence of antibodies to citrullinated pep-
tide derived from PPAD (CPP3) in rats with ligature and 
periodontal pathogen-induced periodontitis and experi-
mental arthritis compared to periodontitis free animals 
with arthritis.
To evaluate the impact of pre-existing periodontitis 
on the development of PIA, a well-established ligature 
model of experimental periodontitis combined with 
swabs containing the oral pathogens P. gingivalis and F. 
nucleatum was used [50, 51]. This combination of bac-
teria was used because the periodontitis-associated P. 
gingivalis has been implicated in the development of 
arthritis and F. nucleatum is known to promote the colo-
nization of P. gingivalis adjacent to the affected teeth [11, 
17]. In addition, polymicrobial infection with these two 
bacteria has been shown to induce a stronger inflam-
matory response compared with infection with either 
bacterium alone [52]. In the current study, severe local-
ized periodontitis, as assessed by tooth mobility, mani-
fested prior to PIA-induction in all experimental animals 
and the loss of alveolar bone was confirmed by intraoral 
radiographs. The assessment of clinical parameters such 
as tooth mobility to study the manifestation of perio-
dontal disease has previously been described in animals 
[38] and is frequently used in humans [53]. The clinical 
manifestations of arthritis in our study were observed 
after 2–3  weeks post pristane injection in all animals, 
followed by a decrease in arthritis disease activity, as 
previously described [44]. The pre-existence of periodon-
titis did not affect the development or disease severity of 
pristane-induced arthritis. In line with our results, Trom-
bone et al. reported no additional effect of periodontitis 
co-induction on the severity of pristane-induced arthritis 
in mice [54]. Conversely, subcutaneous infection with P. 
gingivalis has been reported to exacerbate both collage-
induced arthritis (CIA) in mice and adjuvant arthritis in 
female DA rats [31, 55]. The conflicting results in arthri-
tis severity by periodontitis co-induction may depend 
Table 1 Cytokine profile at  endpoint in  arthritis-affected 
DA rats with and without periodontitis
Mean (range) plasma concentrations (pg/ml) of cytokines (TNF-α, IL-1α, 
IL-1β, IL-2, IL-4, IL-5, IL-7, IL-10, IL-12, IL-13, IL-17, IL-18, EPO, GM-CSF, M-CSF, 
GRO/KC, MIP-3α, RANTES, VEGF and MCP-1) in arthritis rats with and without 
periodontitis, collected at endpoint
DA Dark Agouti, PA rats with experimental periodontitis and pristane-induced 
arthritis, A rats with pristane-induced arthritis without periodontitis, NS not 
significant
* P < 0.05 was considered statistically significant
PA (n = 9) A (n = 12) P value
TNF‑α 110 (3–182) 75 (3–211) NS
IL‑1α 10,608 (2044–18,703) 10,299 (2191–29,782) NS
IL‑1β 20,842 (1170–45,925) 14,170 (1636–41,213) NS
IL‑2 1291 (532–2158) 1046 (282–2283) NS
IL‑4 723 (101–1223) 583 (124–1259) NS
IL‑5 566 (179–798) 469 (224–807) NS
IL‑7 3072 (418–4674) 2540 (526–7174) NS
IL‑10 899 (243–1274) 770 (205–1965) NS
IL‑12 985 (93–1939) 680 (120–1614) NS
IL‑13 243 (14–494) 170 (6–449) NS
IL‑17 214 (39–360) 173 (55–408) NS
IL‑18 2268 (1057–3765) 1449 (445–2673) NS
EPO 780 (436–1079) 536 (145–1231) NS
GM‑CSF 259 (2–778) 127 (2–653) NS
M‑CSF 766 (578–1073) 753 (658–938) NS
GRO/KC 214 (133–294) 150 (66–247) NS
MIP‑3α 227 (49–368) 175 (53–375) NS
RANTES 1028 (402–1628) 735 (356–1280) NS
VEGF 149 (23–286) 102 (20–246) NS
MCP‑1 4407 (1735–7249) 3634 (2499–4867) NS
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on different experimental models of arthritis and peri-
odontitis. Most animal studies that report a more severe 
arthritis by periodontitis co-induction have used CIA 
or collagen antibody-induced arthritis (CAIA) [55–58]. 
Furthermore, different strains of P. gingivalis could also 
affect the results, as not all P. gingivalis strains are equally 
effective in promoting bone loss [59] and could also dif-
fer in their ability to exacerbate arthritis. In the present 
study the well-established animal model of arthritis, the 
PIA model in the rat, was chosen based on its close mim-
icry to human RA [34]. PIA triggers a chronic relaps-
ing arthritis that fulfills many of the RA criteria such as 
symmetrical involvement of peripheral joints, presence 
of rheumatoid factor, cartilage and bone destruction, as 
well as a chronic course of the disease [60]. The arthri-
tis is associated with MHC class II genes [61] and medi-
ated by MHC class II restricted T cells [62, 63] as well as 
with a strong innate immune response [64]. Because the 
disease course in RA can exhibit two different patterns; 
a chronic-persistent [65, 66] or a relapsing-remitting 
[66, 67], the experimental period in this study was set 
to 15  weeks in order to monitor the whole course of 
the disease. To our knowledge, this study with a dura-
tion of 15 weeks is the longest animal study investigating 
the effects of experimental periodontitis on the disease 
course of arthritis, including both active and chronic 
arthritis.
The oral pathogen P. gingivalis, strongly associated 
with periodontitis, has been suggested to be involved in 
the pathogenesis of RA since the presence of P. gingivalis 
DNA has previously been reported in the synovial tis-
sue of RA patients [43], and since patients with RA have 
been shown to have higher anti-P. gingivalis and anti-
RgpB antibody levels, compared to controls [26, 30]. In 
the current study, in line with previously reported data 
[68] P. gingivalis DNA was detected in the oral cavity of 
the periodontitis-affected animals, although the pres-
ence of P. gingivalis in metacarpophalangeal joint tissue 
of periodontitis-affected animals could not be detected. 
To our knowledge, P. gingivalis DNA in synovial tissue in 
experimental animal models has not yet been reported. In 
addition, we were not able to detect P. gingivalis in cul-
tures of oral swabs and ligatures from infected animals at 
endpoint, which may be due to the strict anaerobic nature 
of this pathogen [69], being more sensitive to normal lev-
els of oxygen, P. gingivalis may be less likely to survive 
the long transportation period in our study (up to 8–9 h 
due to practical reasons) for re-cultivation purposes. This 
suggestion is also in line with previous findings reporting 
that only 50% of P. gingivalis are viable after 2 h of incuba-
tion (5% CO2 at 37 °C) and none may survive for 8 h [70]. 
The reigning hypothesis linking periodontitis to RA sug-
gests that P. gingivalis´ ability to secrete the PAD enzyme, 
PPAD, may contribute to the initiation of RA by triggering 
citrullination of proteins in the gingival tissue and break 
immune tolerance, with the subsequent production of 
ACPA. Epitope spreading to other host-citrullinated pro-
teins in the joint could then perpetuate an inflammatory 
process and cause RA [17, 49]. In support of this hypoth-
esis, the results from histological studies have demon-
strated that oral inoculation with P. gingivalis results in 
significantly more bone and cartilage destruction in joints, 
and higher number of osteoclasts and inflammatory cells 
in the periodontium of arthritic mice, as compared to ani-
mals without P. gingivalis infection or P. gingivalis strain 
lacking the PAD enzyme [56, 58]. Considering the central 
role of citrullinated proteins and ACPAs in the etiopatho-
genesis of RA, and the findings suggesting that ACPAs 
may also have a significant impact on the development 
and progression of arthritis in experimental animal mod-
els [26, 71], we have—in the current study—analyzed the 



































Fig. 4 Plasma RgpB, CPP3 and RPP3 levels. Mean plasma concentra‑
tions (AU/ml ± SE) of antibodies against a RgpB, b CPP3 and RPP3 
in arthritis rats with and without periodontitis and healthy control 
animals at endpoint of the experimental period of 15 weeks. *P < 0.05 
was considered statistically significant. PA rats with experimental 
periodontitis and PIA (n = 9), A rats with PIA without periodontitis 
(n = 12), Healthy control rats without induced arthritis or periodon‑
titis (n = 4), RgpB arginine gingipain B, CPP3 citrullinated peptide 
derived from PPAD, RPP3 arginine‑containing (uncitrullinated) PPAD 
peptide
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CPP3 derived from PPAD and CEP-1 derived from 
α-enolase, as well as antibodies against RgpB, one of P. 
gingivalis most potent virulence factors, crucial for PPAD 
citrullination [25, 72, 73]. Our results showed that 89% of 
the periodontitis-affected animals were positive for anti-
bodies against RgpB. Moreover, animals with induced 
periodontitis and arthritis had significantly higher levels 
of autoantibodies against CPP3, as compared to animals 
with arthritis only or healthy controls. The presence of 
citrullinated proteins in the inflamed synovium of arthri-
tis-affected animals has previously been reported in dif-
ferent animal models [74–76], and one study reported a 
non-significant increase in serum ACPA levels in co-mor-
bid mice challenged with both periodontitis (induced by 
oral inoculation with wild-type P. gingivalis) and arthri-
tis, compared to corresponding animals infected with 
PAD-deficient P. gingivalis [58]. A significant increase in 
ACPA levels has also been reported in arthritic mice, after 
a subcutaneous P. gingivalis infection, compared to mice 
infected with a PPAD-knockout strain [55]. However, one 
should keep in mind that animals may express autoanti-
bodies also against the corresponding non-citrullinated 
peptides, making the antibody response not necessarily 
citrulline-specific but rather directed against other parts 
of the peptide, highlighting the importance of uncitrul-
linated negative control antigens when working with 
animal models [77]. Importantly, in our study, signifi-
cantly higher antibody levels in co-morbid rats were only 
detected against CPP3, not against RPP3, as compared to 
the arthritis group. However, we did not detect any anti-
bodies against CEP-1 or the uncitrullinated control pep-
tide REP-1 (data not shown).
The acute phase proteins α-1-AGP and CRP are nor-
mally elevated in plasma as a result of injury, infection 
or inflammation [45, 78]. In patients with RA, α-1-AGP 
positively correlate with erythrocyte sedimentation rate 
(ESR), disease activity and the degree of disability, and 
has therefore been suggested to be a useful biochemi-
cal marker for evaluation of RA disease activity [79]. In 
rats with pristane-induced arthritis, the α-1-AGP levels 
also correlate well with arthritis development [64]. In 
the present study, animals with co-morbid periodontitis 
and arthritis exhibited non-significantly higher plasma 
α-1-AGP at endpoint compared to the arthritis group 
without periodontitis, suggesting a more acute systemic 
inflammation. Concentrations of α-1-AGP followed 
the same pattern in all animals, remaining stable prior 
to pristane injection, irrespective of periodontal sta-
tus, and increased several-fold after arthritis-induction. 
The levels of α-1-AGP were also reflected by the clinical 
manifestations of arthritis progression. The rapid ini-
tial increase in plasma α-1-AGP levels with a peak after 
3 weeks of post arthritis-induction indicated a period of 
acute inflammation followed by a decrease during the 
time of remission of the first acute phase, irrespective of 
periodontal disease. Additionally, the levels of CRP, pre-
viously reported to be associated with periodontitis and 
with anti-P. gingivalis antibody levels in patients with 
RA [2, 21, 80], were also significantly increased both in 
PA and A group post PIA-induction with no significant 
differences between the two groups. Increased levels of 
α-1-AGP and CRP during arthritis in rats have previously 
been reported [64, 81], however, to our knowledge this is 
the first study reporting the levels of α-1-AGP in co-mor-
bid rats with also experimental periodontitis.
Cytokines and chemokines are important key mole-
cules and signal mediators in the pathogenesis of RA and 
periodontitis [19, 82]. Their disease-relevant functions 
include activation of immune cells, fibroblasts, osteo-
clasts and release of proteolytic enzymes that collec-
tively contribute to bone and tissue destruction in both 
RA and periodontitis [19, 82]. Several of the cytokines 
investigated in the present study have been demonstrated 
to serve either as pro-inflammatory (IL-1, IL-12, IL-17, 
IL-18, TNF-α) or anti-inflammatory (IL-4, IL-10) media-
tors of the inflammatory process, or chemokines involved 
in inducing chemotaxis and attracting immune cells to 
the inflammation site (MCP-1, RANTES) [82]. In the 
plasma samples of DA rats, we could not show significant 
differences in the cytokine profiles following periodon-
titis/PIA co-induction. Notably, mean concentrations of 
the investigated cytokines from the animals with coexist-
ing periodontitis and arthritis were higher than in peri-
odontitis free animals, suggesting increased activation of 
immune system due to additional inflammatory stimuli. 
In mice, P. gingivalis induced periodontitis and PIA co-
induction has been reported to increase the levels of 
IL-1ß and IL-17 in periodontal tissue [54]. It is tempting 
to speculate that observed increase in the immune sys-
tem activity might in the long run lead to breach of self-
immunity and development of autoimmune disease.
There are, however, potential limitations with the cur-
rent study we need to take into account. First, the experi-
mental group with periodontitis alone was not included 
in the experiments since the focus of this study was to 
investigate the effect of pre-existing periodontitis on the 
development of arthritis rather than the effect of arthri-
tis on periodontitis. In this context, previous studies have 
showed that experimentally induced arthritis also increase 
periodontal bone loss in rats and mice [32, 56, 58]. Sec-
ondly, no definite interpretations can be drawn about the 
specific effect of P. gingivalis on the development of arthri-
tis, since the experimental periodontitis was induced by 
ligatures in combination with two periodontal pathogens 
to obtain a severe periodontitis and promote the P. gingi-
valis infection (by coaggregation with F. nucleatum) [11]. 
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Finally, the rapid induction and severity of the PIA model 
may be too strong, potentially masking the effects of peri-
odontitis on arthritis development. However, the CIA 
model, also used to investigate the periodontitis-arthritis 
association in mice, is in comparison similar or even more 
severe than the PIA in rats [83]. In this study, a standard-
ized protocol for PIA-induction was chosen, previously 
used by our group and others, to reduce the risk of vari-
ability and increase the possibility of detecting significant 
effects between the study groups [35, 54].
Conclusions
In conclusion, these results suggest that animals with 
arthritis and pre-existing periodontitis, induced by liga-
tures in combination with P. gingivalis and F. nucleatum 
infection, generate higher systemic immune response 
and antibody titers against RgpB and PPAD citrullinated 
peptides, without affecting arthritis disease severity. To 
our knowledge, this is the first animal study reporting 
significantly increased antibody response to PPAD citrul-
linated proteins, following a local oral infection with P. 
gingivalis. The infection by P. gingivalis could potentially 
be the underlying mechanism connecting periodonti-
tis to RA, by giving rise to a systemic immune response 
against citrullinated proteins, with generation of RA spe-
cific antibodies/ACPAs.
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